<DOC>
	<DOC>NCT00097435</DOC>
	<brief_summary>This is a Phase 2, multi-center, randomized, open-label study to evaluate the safety, tolerability, and efficacy of Albuferon in subjects with hepatitis C (HEP C) who failed to respond to previous interferon alfa therapy.</brief_summary>
	<brief_title>A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Major Have a clinical diagnosis of chronic HEP C established on the basis of detectable viral load, as measured by a serum HCV RNA test during the screening period. Have previously failed to respond to treatment with any interferon alfa (IFNa) product Have compensated liver disease with the following minimum criteria: white blood cell count &gt; 3,000/mm3, absolute neutrophil count (ANC) &gt; 2,000/mm3, platelets &gt; 125,000/mm3, and hemoglobin (Hb) &gt; 13 g/dL for males or &gt; 12 g/dL for females. Major Evidence of decompensated cirrhosis or portal hypertension. Pregnant or lactating female. History of any other medical disease or condition that would make the subject (in the opinion of the investigator) unsuitable for the study. A current drug or alcohol addiction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>